21.12.2023 - CAMBRIDGE, Mass., Dec. 21, 2023 (GLOBE NEWSWIRE) - Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that, effective as of December 20, 2023, the Compensation Committee of the Board of Directors granted .
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.
CAMBRIDGE, Mass., Dec. 21, 2023 Vor Bio , a clinical-stage cell and genome engineering company, today announced that, effective as of December 20, 2023, the Compensation Committee of the Board.
Strong strategic and clinical progress in 2023, with multiple catalysts expected in 2024
Launching of two new Founded Entities to advance certain programs from the Wholly Owned Pipeline
Robust.
Vor Biopharma Inc (NYSE:VOR) Receives Average Rating of Buy from Analysts themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.